MONMOUTH JUNCTION, N.J.,
June 19, 2015 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its CytoSorb® blood
purification technology to reduce deadly uncontrolled inflammation
in hospitalized patients around the world, is set to join the
Russell Microcap® Index at the
conclusion of the Russell indexes annual reconstitution on
June 26, 2015, according to a
preliminary list of additions posted on June
12, 2015.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "We are pleased to be included in
the Russell Microcap Index, a significant corporate achievement
that is expected to increase visibility and exposure of our company
and life-saving technology to the broader investment
community. This complements our continued institutional
investor outreach, where the response has been extremely positive
to date."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the
Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell 1000 and the Russell indexes
reconstitution, go to "Recon Central" section on the FTSE Russell
website.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 80 countries,
covering 98% of the investable market globally and trading on over
25 exchanges worldwide.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Leading asset
owners, asset managers, ETF providers and investment banks use FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance. FTSE Russell is also focused on
index innovation and client collaboration as it seeks to enhance
the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group. For
more information, visit www.ftserussell.com.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is
the cause of nearly half of all deaths in the intensive care unit,
with little to improve clinical outcome. CytoSorb®, the
Company's flagship product, is approved in the European Union with
distribution in 29 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also
being used during and after cardiac surgery to remove inflammatory
mediators, such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's
websites: http://www.cytosorbents.com and
http://www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2015, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and
Twitter
Cytosorbents
Contact: Amy Vogel
Investor
Relations
(732) 329-8885 ext.
*825
avogel@cytosorbents.com
|
|
Investor
Contact:
Lee Roth
The Ruth
Group
646-536-7012
lroth@theruthgroup.com
Public Relations
Contact:
Melanie
Sollid-Penton
The Ruth
Group
646-536-7023
msollid@theruthgroup.com
|
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-corporation-set-to-join-russell-microcap-index-300101904.html
SOURCE CytoSorbents Corporation